iHuman Inc - ADR Aktie News

BEIJING, June 29, 2026 /PRNewswire/ -- iHuman Inc. (NYSE: IH) ("iHuman" or the "Company"), a leading provider of tech-powered knowledge and personal growth products, today announced its unaudited financial results for the first quarter ended March 31, 2026.   First Quarter 2026 Highlights Revenues were RMB182.5 million (US$26.5 million), compared with RMB210.4 million in the same period last year.

New late-breaking data presentations underscore Jazz's significant progress in advancing holistic understanding of narcolepsy and idiopathic hypersomnia, including novel real-world evidence of meaningful changes in cardiometabolic risk markers following Xywav initiation For U.S. media and investors only DUBLIN, June 16, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announce...

BEIJING, May 31, 2026 /PRNewswire/ -- iHuman Inc. (NYSE: IH) ("iHuman" or the "Company"), a leading provider of tech-powered, intellectual development products in China, today announced that it has entered into certain asset transfer agreements to acquire the businesses and assets related to two products, All Knowledge (全知识) and Perfect Lingo (万词王) (the "Acquisitions"), for an aggregate conside...

BEIJING, April 24, 2026 /PRNewswire/ -- iHuman Inc. (NYSE: IH) ("iHuman" or the "Company"), a leading provider of tech-powered, intellectual development products in China, today announced that it filed its annual report on Form 20-F for the year ended December 31, 2025 with the U.S. Securities and Exchange Commission on April 24, 2026. The annual report on Form 20-F is available on the Company'...

BEIJING, March 31, 2026 /PRNewswire/ -- iHuman Inc. (NYSE: IH) ("iHuman" or the "Company"), a leading provider of tech-powered, intellectual development products in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2025.  Fourth Quarter 2025 Highlights Revenues were RMB190.7 million (US$27.3 million), compared with RMB232.7 million ...